PT - JOURNAL ARTICLE AU - Strumann, Christoph AU - Ranzani, Otavio AU - Moor, Jeanne AU - Berner, Reinhard AU - Töpfner, Nicole AU - Chao, Cho-Ming AU - Moor, Matthias B. TI - Vaccine effectiveness of BNT162b2 mRNA Covid-19 Vaccine in Children below 5 Years in German Primary Care AID - 10.1101/2023.05.05.23289209 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.05.23289209 4099 - http://medrxiv.org/content/early/2023/05/08/2023.05.05.23289209.short 4100 - http://medrxiv.org/content/early/2023/05/08/2023.05.05.23289209.full AB - Background Despite the approval of BNT162b2 mRNA vaccine for children aged 6 months to 4 years by the European Medicines Agency (EMA) and the Federal Drug Administration (FDA) in 2022, no data on vaccine effectiveness (VE) of BNT162b2 are available in this age group. We here report on the VE of BNT162b2 during an Omicron BA.1-2 dominant period.Methods An authentication-based retrospective survey was performed between April 14th 2022 and May 9th 2022 in individuals that had registered children for off-label SARS-CoV-2 vaccination in Germany. We used Cox regression to estimate relative VE of two BNT162b2 doses, with the period between first and second vaccine dose as reference period (24.8+-0.6 days) and >=7 days after Dose 2 to before Dose 3 as post-vaccination period (59.5+-23.6 days).Results The present analysis included 4615 children aged 2.8+-1.2 years (mean+-standard deviation) who had received their first dose of BNT162b2 on January 1st 2022 or thereafter. VE was substantial for protection from any SARS-CoV-2 infection (VE: 53.1% [95% confidence interval (CI): 36.3-69.6%], p<0.001), symptomatic SARS-CoV-2 infections (VE: 57.5% [95% CI: 40.8-74.2%], p<0.001), and SARS-CoV-2 infections leading to medication use (VE: 66.2% [95% CI: 43.7-88.7%], p<0.001). Differences in dosage of BNT162b2 yielded no change in VE.Conclusion This study offers a first industry-independent insight in the potential VE of two doses of the BNT162b2 vaccine in children aged below 5 years, as currently only immunogenicity data by the manufacturer Pfizer/BioNTech are available. Limitations include the retrospective study design, and that the reported VE does not necessarily correspond to currently circulating SARS-CoV-2 variants.Competing Interest StatementOR is supported by the Sara Borrell Fellowship from the Instituto de Salud Carlos III (CD19/00110). JM received funding from the Gottfried & Julia Bangerter-Rhyner Foundation. NT and RB were supported by the coverCHILD project of the German Network University Medicine. RB was also supported by the Federal Ministry of Education and Research (BMBF), Germany, and the Saxon State Ministry for Science and the Arts (SMWK), Federal State of Saxony, Germany. CMC was supported by University Medical Center Rostock. MBM is supported by the Swiss National Science Foundation (grant no. 214187).Funding StatementOR is supported by the Sara Borrell Fellowship from the Instituto de Salud Carlos III (CD19/00110). JM received funding from the Gottfried & Julia Bangerter-Rhyner Foundation. NT and RB were supported by the coverCHILD project of the German Network University Medicine. RB was also supported by the Federal Ministry of Education and Research (BMBF), Germany, and the Saxon State Ministry for Science and the Arts (SMWK), Federal State of Saxony, Germany. CMC was supported by University Medical Center Rostock. MBM is supported by the Swiss National Science Foundation (grant no. 214187).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of University of Rostock, Germany gave ethical approval for this work (study ID: A2022-0065).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw data are available from the corresponding author on request, provided that a positive evaluation by the pertinent ethics committee is available and German data protection laws are followed.